This company is no longer in business. Investors can get details about any potential exits or failures here.
Facible BioDiagnostics
Growth Stage
Leading the Biodiagnostic Testing Revolution
Overview
Platform
Rialto Markets
Start Date
07/27/2022
Close Date
Not Provided
Min. Goal
$1,000
Max. Goal
$40,000,000
Min. Investment
$1,000
Security Type
Equity - Common
Series
Series A
SEC Filing Type
RegA+
Price Per Share
$5.80
Pre-Money Valuation
$702,724,398
Year Founded
2022
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
High
Capital Intensity
High
Facible BioDiagnostics is raising funds on Rialto Markets through Reg A+ crowdfunding. The company has developed a new technology for diagnostic testing to deliver fast and accurate results in the detection of viruses, bacteria, and other contaminants. The technology is called Quantum-Logic Anazyme Analyte Detection (Q-LAAD) and is specifically used for COVID testing. Facible BioDiagnostics has signed an LOI with a distributor for 18 million units and estimates its gross profit margin to be 93.57%. Steven Burden, Clementine Gibard Bohachek, and Hunter Covert founded Facible BioDiagnostics in 2022. The current crowdfunding campaign has a maximum target of $40,000,000. The campaign proceeds will be used for research and development, clinical testing, and working capital.
Balance Sheet
|
Cash and Cash Equivalents |
$449,114 |
|
Property, Plant and Equipment (PP&E) |
$697,197 |
| Total Assets |
$1,432,437 |
|
Accounts Payable & Accrued Liabilities |
$246,663 |
|
Long Term Debt |
$8,805,465 |
|
Total Liabilities |
$9,070,128 |
|
Total Stockholders' Equity |
$-7,637,691 |
| Total Liabilities and Equity |
$1,432,437 |
Statement of Comprehensive Income Information
|
Costs & Expenses Applicable to Rev |
$2,205,884 |
|
Depreciation and Amortization |
$135,815 |
| Net Income |
$-6,377,124 |
|
Earnings Per Share - Basic |
$-0.29 |
|
Earnings Per Share - Diluted |
$-0.09 |
Auditor: Assurance Dimensions
Financials as of: 07/27/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.